Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
about
Target of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipientsTarget of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipientsUrban legends: recurrent aphthous stomatitisMetabolic consequences of modern immunosuppressive agents in solid organ transplantationCurrent state of renal transplant immunosuppression: Present and futureThe use of novel diagnostics to individualize immunosuppression following transplantationUrinary tract infection in renal transplantationCorticosteroid and calcineurin inhibitor sparing regimens in kidney transplantationA systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipientsProtective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signalingEverolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateImproving the outcome of kidney transplantation by ameliorating renal ischemia reperfusion injury: lost in translation?Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus.Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain.Rapamycin blocks fibrocyte migration and attenuates bronchiolitis obliterans in a murine model.Short-course rapamycin treatment preserves airway epithelium and protects against bronchiolitis obliteransThe pros and the cons of mTOR inhibitors in kidney transplantation.Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant.More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response.mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK.Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation.Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipientsA randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.Deferred pre-emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of T regulatory cell population: a randomized, controlled trial.Cellular effects of everolimus and sirolimus on podocytes.Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years.Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantationMinimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015?Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials.Activation of the Mammalian Target of Rapamycin in the Rostral Ventromedial Medulla Contributes to the Maintenance of Nerve Injury-Induced Neuropathic Pain in RatThe Peripheral NK Cell Repertoire after Kidney Transplantation is Modulated by Different Immunosuppressive DrugsCampath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocolInhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation.Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.Outcomes in ethnic minority renal transplant recipients receiving everolimus versus mycophenolate: comparative risk assessment results from a pooled analysis.Clinical application of mTORi based immunosuppression for renal transplantation in India.Role of everolimus in pancreatic neuroendocrine tumors.Everolimus: preventing organ rejection in adult kidney transplant recipients.
P2860
Q24187866-6282C054-595F-4D28-9F71-542EBD339C8BQ24201591-0093E204-4C01-4823-8A67-69A7CDA0CEC7Q24635082-20EA6777-5EA1-40A5-BA35-E7BDF4C723A7Q26746936-513BAC14-42D3-424D-A71E-23A874E4A033Q26829789-F6E5F0E9-D3DB-4B58-9748-F8EE1B38E570Q26864686-87F23A4A-7905-41E8-A5CA-B321953DA35BQ26991858-F7D939BA-8725-4BC6-A134-35F1DCAD89AAQ26992343-1F60649F-C96A-4D15-9AC3-8D3BBA5588BAQ27000107-710EDF96-FFE9-4F16-99C7-376669F30468Q27315815-CF10AFD9-B7AF-4817-A93A-30083FA0D3DBQ28067598-70C8D337-3A3B-4845-A434-0B41F08704ADQ28069954-244A085E-A094-4B8E-AE0F-25EEE0DF1E88Q30301338-0EFD12EF-84BB-4FF3-A500-1122783A423DQ30383901-A7331144-F631-44FD-9C02-F3A2F3B1932DQ30409683-7B9D1D4F-5851-421C-912C-DD8F9C2B7A57Q30411470-181E46D3-0DBE-436F-B10E-E12A8FA2B12EQ33412367-0946F9B7-8147-4163-B33E-F09D114FA28BQ33617408-B499A7FC-B344-40E9-B7B5-76797DB909C7Q34023028-EBD317BA-4936-4AB8-A189-DA81A6EEF757Q34303766-E29B9804-CC28-494B-ACE8-9F3C28482F04Q34340709-1F0B006F-D555-46EF-94F6-66B5430591AAQ34638056-D83383D8-94E6-45FA-B6E6-0756BA72AD3DQ34753440-F4C34F63-1948-404D-BF9F-0368CC8185C9Q34805919-B1797A29-1645-4B37-8737-B46B84C6B54FQ34995106-6213A2B0-8545-4DF9-9762-A5D8A805443AQ35022430-F2F7D297-E73D-432A-8442-9517FE6F5D5BQ35048950-0B577091-9287-4BBF-ACB6-863C9D23A06CQ35776408-3A2167B2-1F6A-4903-8C6C-069C949F0B19Q35953320-C6A6F02B-4D93-4384-8C1A-D0E09D168379Q36087779-0BBBA3C3-1F06-4A1D-A576-95A2EBD83F24Q36255504-C95D8691-9E71-460D-9196-EB554FA4E954Q36386694-334B5B66-2B33-461D-A84F-DD00A952D6A0Q36644337-61C99AD2-8448-40E1-BADB-55337339B16CQ36908763-D0FEC772-0CBF-4E37-A571-D45ADAFE008AQ37184425-ECF8157A-F00A-40E1-993E-6580099CF648Q37337337-D220AB44-1418-418F-8C62-F0155899ECE1Q37464878-9AE1759A-96D1-4319-B842-A6DA94143D91Q37929851-0EF26F4F-6C4D-4504-9965-DF866962C84FQ37935772-C74482A6-2193-4829-98B0-457585668625Q37992135-290B5DF9-A0B3-40E4-8664-D9A6E3A368CC
P2860
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Everolimus-based, calcineurin- ...... randomised, controlled trial.
@ast
Everolimus-based, calcineurin- ...... randomised, controlled trial.
@en
type
label
Everolimus-based, calcineurin- ...... randomised, controlled trial.
@ast
Everolimus-based, calcineurin- ...... randomised, controlled trial.
@en
prefLabel
Everolimus-based, calcineurin- ...... randomised, controlled trial.
@ast
Everolimus-based, calcineurin- ...... randomised, controlled trial.
@en
P2093
P1433
P1476
Everolimus-based, calcineurin- ...... randomised, controlled trial.
@en
P2093
Claudia Sommerer
Frank Pietruck
Harald Gschaidmeier
Klemens Budde
Stefan Kramer
Thomas Becker
Wolfgang Arns
Wolfgang Fischer
ZEUS Study Investigators
P304
P356
10.1016/S0140-6736(10)62318-5
P407
P577
2011-02-19T00:00:00Z